Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies ; volume:24 ; number:1 ; day:5 ; month:12 ; year:2024 ; pages:1-8 ; date:12.2024
BMC cancer ; 24, Heft 1 (5.12.2024), 1-8, 12.2024
- Creator
-
Andrikopoulou, Angeliki
Zagouri, Flora
Goula, Kallirroi
Haidopoulos, Dimitrios
Thomakos, Nikolaos
Svarna, Anna
Dimopoulos, Meletios-Athanasios
Liontos, Michalis
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-024-13226-1
- URN
-
urn:nbn:de:101:1-2502192121119.736704017045
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:25 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Andrikopoulou, Angeliki
- Zagouri, Flora
- Goula, Kallirroi
- Haidopoulos, Dimitrios
- Thomakos, Nikolaos
- Svarna, Anna
- Dimopoulos, Meletios-Athanasios
- Liontos, Michalis
- SpringerLink (Online service)
Other Objects (12)
The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2
Approaches to prevention of gynecological malignancies
Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02
ICG-enhanced fluorescence-guided SLN mapping in gynecological malignancies
ICG-enhanced fluorescence-guided SLN mapping in gynecological malignancies
Recent Advances in Gynecological Malignancies: Focus on ASCO 2023
Mitophagy in gynecological malignancies: roles, advances, and therapeutic potential
A prospective, non-randomized phase II trial of Trastuzumab and Capecitabine in patients with HER2 expressing metastasized pancreatic cancer
Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer
Circulating MicroRNAs in gynecological malignancies: from detection to prediction
68Ga-FAPI-PET/CT in patients with various gynecological malignancies
Photoimmunotherapy of HER2-expressing Breast Cancer Cells
The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2
Approaches to prevention of gynecological malignancies
Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02
ICG-enhanced fluorescence-guided SLN mapping in gynecological malignancies
ICG-enhanced fluorescence-guided SLN mapping in gynecological malignancies
Recent Advances in Gynecological Malignancies: Focus on ASCO 2023
Mitophagy in gynecological malignancies: roles, advances, and therapeutic potential
A prospective, non-randomized phase II trial of Trastuzumab and Capecitabine in patients with HER2 expressing metastasized pancreatic cancer
Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer
Circulating MicroRNAs in gynecological malignancies: from detection to prediction
68Ga-FAPI-PET/CT in patients with various gynecological malignancies
Photoimmunotherapy of HER2-expressing Breast Cancer Cells
The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2
Approaches to prevention of gynecological malignancies
Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02
ICG-enhanced fluorescence-guided SLN mapping in gynecological malignancies
ICG-enhanced fluorescence-guided SLN mapping in gynecological malignancies
Recent Advances in Gynecological Malignancies: Focus on ASCO 2023
Mitophagy in gynecological malignancies: roles, advances, and therapeutic potential
A prospective, non-randomized phase II trial of Trastuzumab and Capecitabine in patients with HER2 expressing metastasized pancreatic cancer
Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer
Circulating MicroRNAs in gynecological malignancies: from detection to prediction
68Ga-FAPI-PET/CT in patients with various gynecological malignancies